Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposome bupivacaine vs ropivacaine adductor canal block in knee arthroplasty
ChiCTR2300076174Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in knee osteoarthritis (OA) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoints: Remifentanil dosage, VAS score (resting) and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
bupivacaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2300076174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076174.